Recent research have converged on the overlap of GLP|GIP|GCGR stimulant therapies and dopaminergic communication. While GLP activators are widely employed for addressing type 2 diabetes mellitus, their potential impacts on reward circuits, specifically mediated by DA systems, are receiving substa